Skip to content
Menu

Xenon Pharmaceuticals Inc. XENE

Full chart Compare
Set alert

Price alert · XENE

All alert types
37.12 USD -0.44 (-1.17%)

As ofNov 20, 2026, 2:57 PM EST

36.97 Day range 37.97
33.38 52-week range 72.66
YTD
-17.18%
1 year
-7.82%

5D -3.32 (-8.11%)

3840FriMonTueWedThu37.61
Market cap
3.65B
EPS (ttm)
-4.69
Shares out
98.28M
Forward P/E
-8.04
YTD return
-17.18%
1-year return
-7.82%
50-day average
39.88
200-day average
52.23
Enterprise value
2.77B
Price / book
3.22
Volume
519.86K
Avg volume
1.68M
Open
37.22
Previous close
37.56
Day's range
36.97 – 37.97
52-week range
33.38 – 72.66
Beta
0.08
Analysts
Strong Buy
Price target
71.56 (+92.8%)
Earnings date
Feb 25, 2027

Key statistics

Free cash flow
-209.31M
Total cash
950.80M
Total debt
6.01M
Return on equity
-50.27%
Short % of float
7.50%

Fundamental scorecard

4 of 25 checks passed on XENE’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 1 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
XENE Revenue — quarterly 0
XENE Net income — quarterly -110.44M
XENE EPS — quarterly -1.11

Earnings

XENE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 25, 2027Dec 30, 2026-1.14———
Nov 9, 2026Sep 30, 2026-1.13-1.11+0.02+1.77%
Aug 6, 2026Jun 30, 2026-1.14-1.11+0.03+2.63%
May 7, 2026Mar 31, 2026-1.17-1.170.000.00%
Feb 26, 2026Dec 31, 2025-1.20-1.31-0.11-9.17%
Nov 3, 2025Sep 30, 2025-1.16-1.15+0.01+0.86%

Upgrades / downgrades

XENE analyst upgrades and downgrades
DateFirmActionFromTo
Sep 18, 2026RBC CapitalmainOutperformOutperform
Sep 18, 2026WedbushmainOutperformOutperform
Sep 18, 2026Wells FargomainOverweightOverweight
Sep 18, 2026Deutsche BankdownBuyHold
Sep 18, 2026NeedhammainBuyBuy
Sep 18, 2026BairdmainOutperformOutperform

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Sector
Healthcare
Industry
Biotechnology
Country
Canada

News

Your note

Sign in to keep a note on XENE — it syncs with the Stock Master app.

Insider holders

XENE insider holders
InsiderRelationLatest transactionDateShares held
CANNON GILLIANDirectorSaleJun 4, 20261,455
DIFABIO ANDREAOfficerSaleMar 12, 20267,301
GANNON STEVENDirectorSaleAug 10, 20261,870
GAROFALO ELIZABETH AMY M.D.DirectorConversion of Exercise of derivative securityMay 31, 20262,645
GOVER JUSTIN DAVIDDirectorConversion of Exercise of derivative securityMay 31, 20262,645
KELLY THOMAS PATRICKChief Financial OfficerPurchaseSep 29, 202615,000

Institution ownership

XENE institution ownership
Holder% heldSharesValueReported
FMR, LLC11.95%11,554,454433.99MSep 29, 2026
T. Rowe Price Investment Management, Inc.8.17%7,896,803296.60MSep 29, 2026
Blackrock Inc.7.98%7,710,413289.60MSep 29, 2026
Avoro Capital Advisors LLC5.69%5,500,000206.58MSep 29, 2026
Polar Capital Holdings PLC5.20%5,022,084188.63MSep 29, 2026
Janus Henderson Group Ltd.4.14%4,002,869150.35MSep 29, 2026

Fund ownership

XENE fund ownership
Holder% heldSharesValueReported
Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total 3.71%3,583,633134.60MSep 29, 2026
SmallCap World Fund Inc2.91%2,814,992105.73MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF2.63%2,537,75095.32MSep 29, 2026
T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App1.32%1,274,67347.88MJun 29, 2026
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund1.11%1,074,45840.36MAug 30, 2026
JPMorgan Trust II-JPMorgan Mid Cap Growth Fund1.00%962,10136.14MJun 29, 2026